Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

ENHERTU® (trastuzumab deruxtecan) Receives Time-Limited Reimbursement Recommendation from Canada's Drug Agency for Gastric Cancer May 23, 2025 8:05 AM ET AstraZeneca PLC (AZN) ...

In the DESTINY-Breast06 trial, trastuzumab deruxtecan demonstrated a 36% reduction in the risk of disease progression or death compared with chemotherapy (HR, 0.64; 95% CI, 0.54-0.76; P < .0001 ...

HERCESSI™, a biosimilar to Herceptin®, is the first FDA-approved biosimilar from Accord BioPharma, with several more in development DURHAM, N.C., April 29, 2024 /PRNewswire/ -- Accord BioPharma ...

Accord BioPharma, Inc. announces U.S. food & drug administration approval of HERCESSI (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab) for the treatment of several forms of HER2 ...

Herceptin (trastuzumab) is a prescription drug that’s used to treat certain types of breast cancer and stomach cancer. Herceptin can cause side effects that range from mild to serious.

A Prescription Drug User Fee Act target date has been set for the second quarter of 2024. References: Enhertu® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients ...

Other Herceptin biosimilars currently on the market include Amgen and Allergan’s Kanjinti. The biosimilar was approved by the US Food and Drug Administration (FDA) in 2019. The drug generated $20m in ...

New Delhi: Beta Drugs Limited (Adley Group), is a leading pharmaceutical company committed to providing innovative healthcare solutions. Is foraying into the biosimilars market with the ...

The drug is used for HER2-positive breast cancer and is being marketed in India under the brand name ‘ Trumab’. Trumab’s, a 440 mg vial will now be priced at Rs 15,749.